Table 3.
Toxicity in patients with solid tumors who underwent tandem autologous stem cell transplantation, n (%)
| Parameter |
First ASCT
|
Second ASCT
|
||
|
Group A (n = 21)
|
Group B (n = 19)
|
Group A (n = 21)
|
Group B (n = 19)
|
|
| Hematologic toxicity | ||||
| Fever (BT ≥ 38.0 °C) | 17 (81.1) | 18 (94.7) | 17 (80.1) | 16 (84.2) |
| Septicemia | 2 (9.5) | 1 (5.3) | 0 (0) | 0 (0) |
| Non-hematologic toxicity | ||||
| Mucositis | 1 (4.8) | 3 (15.8) | 2 (9.5) | 5 (26.3) |
| Vomiting | 14 (66.7) | 16 (84.2) | 12 (57.1) | 11 (57.9) |
| Diarrhea | 10 (47.6) | 13 (68.4) | 10 (47.6) | 11 (57.9) |
| Elevated liver enzymes | 4 (19.0) | 4 (21.1) | 1 (4.7) | 4 (21.1) |
| Renal insufficiency | 0 (0) | 1 (5.3) | 0 (0) | 1 (5.3) |
| Hypokalemia | 5 (23.8) | 10 (52.6) | 2 (9.5) | 4 (21.1) |
| Hypomagnesemia | 8 (38.0) | 6 (31.6) | 7 (33.3) | 2 (10.5) |
| Hepatic VOD | 0 (0) | 0 (0) | 0 (0) | 3 (15.8) |
| Myocarditis | 2 (9.5) | 1 (5.3) | 0 (0) | 0 (0) |
| Treatment-related mortality | 0 | 0 | ||
ASCT: Autologous stem cell transplantation; BT: Body temperature; VOD: Veno-occlusive disease.